Skip to Content

Fosaprepitant Disease Interactions

There are 2 disease interactions with fosaprepitant:

Moderate

Fosaprepitant (applies to fosaprepitant) QT prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome

Fosaprepitant, a prodrug of aprepitant, is a weak inhibitor of CYP3A4, and aprepitant is a substrate, inhibitor, and inducer of CYP3A4. An increased plasma concentration of fosaprepitant could cause QT prolongation. Caution is advised in patients with long QT, and in patients receiving other drugs that are CYP3A4 substrates as it may result in a risk of higher plasma concentrations and adverse events. Close monitoring is recommended in these patients.

Moderate

Fosaprepitant (applies to fosaprepitant) severe hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh greater than 9), therefore caution and monitoring is recommended when using fosaprepitant in these patients.

Fosaprepitant drug interactions

There are 387 drug interactions with fosaprepitant

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.